CD8A and cancer: Immunotherapy of cancer has made significant progress with the recent introduction of new therapeutic reagents, such as antibodies specific for CTLA, PD-1, and PDL-1, so-called immune “checkpoints.” Yet, we still need robust techniques allowing the rapid identification and isolation of CD8 T cells of optimal avidity and functions against tumors.